Clinical trials: Guillain-Barre Syndrome

Group B Streptococcus

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women

• Completed
• Age: 18 to 40 years
• Phase 1
• Vaccines
• Results posted

This study will evaluate the safety and immunogenicity of a Group B Streptococcus vaccine.

Trial name

NCT01150123

Testing

Group B streptococcus (GBS) vaccine- low dose, Group B streptococcus (GBS) vaccine- High dose

Where

Belgium

Volunteers

678 people, healthy volunteers welcome

Sponsor

Novartis Vaccines